Per-patient Comparison of [68Ga]-FAPI-46 Versus [18F]FDG as PET Tracers in ER-positive Breast Cancer: Study Design of a Single-centre Prospective Study
Introduction. [18F]FDG can be considered as PET tracer to determine whole-body staging in patients with locally advanced (LABC), metastatic, and recurrent breast cancer. Yet, previous studies demonstrated a lower amount of metabolic accumulation on [18F]FDG PET in case of oestrogen receptor (ER)-positive breast cancer....